Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
Clinical trial NCT07279766 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07279766
- Sponsor
- Tor Biering-Sørensen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-11
- Primary completion
- 2026-08-01
- Enrollment
- 285000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.